Aerie Pharmaceuticals, Inc. (AERI) Stake Lessened by Alliancebernstein LP

Lloyd Doyle
September 23, 2017

The other 8 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it.

Based on the latest brokerage notes which have been released to investors, 2 brokers have issued a rating of "strong buy", 6 brokers "buy", 1 brokers "neutral", 0 brokers "sell" and 0 brokers "strong sell". The lowest price the stock reached in the last trading day was $3.82 and compares with the $3.15 52-week low.

Short traders are feeling a little more bearish on shares of the company as evidenced by the rise in short interest.

03/09/2017 - Aerie Pharmaceuticals, Inc. was downgraded to "market perform" by analysts at Raymond James.

Many investors enter the stock market without a plan in place. Aerie Pharmaceuticals has a 12 month low of $12.56 and a 12 month high of $51.85.

The counter witnessed a trading volume of 1.94 million shares versus an average volume of 1.98 million shares during last trading session. Moreover, Dekabank Deutsche Girozentrale has 0.01% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 15,900 shares. It has outperformed by 163.50% the S&P500. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company's stock. Therefore 100% are positive. Aerie Pharmaceuticals had 32 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 17 by Stifel Nicolaus. Cowen & Co maintained the shares of AERI in report on Wednesday, August 2 with "Buy" rating. The rating was initiated by JMP Securities with "Market Outperform" on Wednesday, September 9. The firm has "Outperform" rating given on Wednesday, November 4 by RBC Capital Markets.


COPYRIGHT VIOLATION NOTICE: "Aerie Pharmaceuticals, Inc". The firm has "Buy" rating given on Thursday, September 15 by Cantor Fitzgerald. The firm earned "Buy" rating on Thursday, September 15 by Cantor Fitzgerald. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The total value of its holdings increased 23.2%.

Since May 9, 2017, it had 1 insider purchase, and 1 sale for $1.08 million activity. Needham & Company raised the price objective on stocks of Aerie Pharmaceuticals from $58.00 to $65.00 and issued the shares a "buy" recommendation in a analysis note on early Thur, May 25th.

Investors sentiment increased to 1.17 in 2017 Q2. Its down 1.36, from 2.49 in 2016Q3.

Aerie Pharmaceuticals, Inc.is a clinical-stage pharmaceutical company. Harvey Capital owns 26,700 shares for 0.6% of their portfolio. Bancorporation Of America De reported 69,344 shares. Moreover, Blackrock Fund Advsr has 0.01% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 1.63M shares.

The share price of the company (AERI) was down -2.50%, with a high of 60.28 during the day and the volume of Aerie Pharmaceuticals, Inc. shares traded was 368388. Schwab Charles Invest invested in 0.01% or 134,718 shares. (NASDAQ:AERI) Cheap From Peers? The fund owned 82,590 shares of the company's stock after acquiring an additional 19,060 shares during the quarter. Thrivent Financial For Lutherans owns 109,130 shares. Endurant Cap Mgmt Limited Partnership invested in 0.98% or 62,630 shares. Northern Trust Corp raised its stake in Aerie Pharmaceuticals by 6.6% during the second quarter. Bnp Paribas Arbitrage owns 463 shares. Boulegeris Investments reported 79,525 shares.

05/25/2017 - Aerie Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at H.C. Wainwright. Although growth stocks can be a bit riskier, they can also provide a higher level of reward down the line. With short interest at 5,230,594 and short average daily volume at 414,537, the short-interest ratio is 13.0 and the percentage of shorted shares was 0.15% on August 31. Fossil Group, Inc. earnings have declined with an annualized rate of -18.7% over the last 5 years. CUBE's profit will be $72.01 million for 16.46 P/E if the $0.40 EPS becomes a reality. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.84) by $0.02.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER